*KRAS* mutations are predictive markers for the poor efficacy of anti-EGFR antibody therapies in patients with metastatic colorectal cancer ([@bib21]; [@bib7]; [@bib10]; [@bib12]; [@bib18]; [@bib2]; [@bib9]; [@bib13]; [@bib17]; [@bib20]). Point mutations in the *KRAS* gene occur early in the progression from colorectal adenoma to carcinoma and are detected in 35--40% of patients, regardless of their Dukes stage ([@bib4]). More than 90% of the *KRAS* mutations in these patients have been detected in codons 12 (GGT) and 13 (GGC) ([@bib24]). Activating mutations at codons 61 and 146 have also been reported in a small number of these tumours. In addition, mutations in the molecules involved in signalling pathways downstream of EGFR, such as *NRAS*, *BRAF* and *PIK3CA*, have also been reported in colorectal cancers. These mutations have been suggested to modify the efficacy of anti-EGFR antibody therapies, although their predictive value has not yet been established ([@bib8]).

Oxaliplatin \[*trans*-R,R-1,2-diaminocyclohexaneoxalatoplatinum (II), L-OHP\] is a third-generation platinum (Pt)-containing anti-tumour compound. It is frequently administered as a component of FOLFOX therapy in combination with 5-FU for patients with metastatic colorectal cancer. Oxaliplatin induces DNA damage associated with intra- and inter-strand cross-links (Pt-GG adducts) and can induce gene mutations ([@bib32]; [@bib15]; [@bib28]). The mutagenic activity of oxaliplatin has been demonstrated in cultured cells ([@bib29]).

The *KRAS* mutation status of primary and metastatic lesions is reportedly highly concordant ([@bib25]; [@bib22]; [@bib30]; [@bib33]; [@bib31]; [@bib11]; [@bib27]; [@bib14]; [@bib23]; [@bib26]; [@bib5]; [@bib16]; [@bib19]). However, whether long-term treatment with genotoxic chemotherapies, such as oxaliplatin, can induce additional mutations in metachronous metastatic lesions has not yet been well examined.

Assuming that FOLFOX therapy has the potential to alter the biomarker mutation profile, it is important to determine whether the primary or relapsed tumour represents the more appropriate source of DNA for testing. We examined the mutation status of *KRAS* and other biomarker genes in primary and synchronous/metachronous metastatic lesions in patients with stage III/IV colorectal cancer treated with adjuvant FOLFOX therapy following curative resection.

Patients and methods
====================

Patient selection
-----------------

A total of 63 lesions from 21 patients who had received adjuvant FOLFOX therapy for stage III/IV colorectal cancer following curative resection at the National Cancer Center Hospital East, Japan, between January 2006 and December 2009 were examined.

All patients were treated with a modified FOLFOX6 regimen, with a reduced oxaliplatin dose of 85 mg m^−2^ administered every 14 days, and 12 cycles were planned as the full therapy course ([@bib3]; [@bib1]). FOLFOX therapy was discontinued when tumour relapse was demonstrated by imaging or when intolerable adverse events occurred.

DNA samples and mutational analyses
-----------------------------------

The DNA samples were obtained from macroscopically dissected formalin-fixed paraffin-embedded specimens cut into 10-*μ*m-thick sections. Genomic DNA was extracted using the EZ1 Advanced XL and EZ1 DNA Tissue Kits (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions ([@bib6]). Mutations in *KRAS* codons 12 and 13 were detected using the ARMS/Scorpions technology-based *KRAS* PCR Kit (Qiagen) according to the manufacturer\'s instructions. Mutations in *KRAS* codons 61 and 146, *NRAS* codons 12, 13 and 61, *BRAF* codon 600 and *PIK3CA* codons 542, 545, 546 and 1047 were detected using the multiplex PCR-Luminex method-based MEBGEN Mutation Kit (Medical & Biological Laboratories, Nagoya, Japan). Mutations detected with the MEBGEN Mutation Kit were confirmed by direct sequencing. Mutations in *PIK3CA* codons 542, 545 and 546 were further confirmed using the ARMS/Scorpions technology-based PI3K Mutation Test Kit (Qiagen). The study was approved by the Institutional Review Board of the National Cancer Center.

Results
=======

Patient and tumour site characteristics
---------------------------------------

We reviewed 151 consecutive cases of stage III/IV colorectal cancer treated with an adjuvant FOLFOX therapy after curative resection. Among these cases, 21 patients developed metastatic tumours that were diagnosed during or after the FOLFOX therapy and surgically resected. The patient and tumour site characteristics are shown in [Table 1](#tbl1){ref-type="table"}. The primary tumour sites were the colon and rectum in 8 and 13 patients, respectively. The most abundant primary tumour histopathological type was differentiated adenocarcinoma. Well- and moderately differentiated adenocarcinomas and mucinous adenocarcinomas were observed in 5, 14 and 2 patients, respectively. All metastatic tumours exhibited histology concordant with that of the associated primary colorectal adenocarcinoma.

In all, 12 patients had stage III disease, whereas the remaining 9 patients had synchronous metastatic lesions and were diagnosed as stage IV at the initial operation. There were 12 synchronous metastatic lesions in the patients with stage IV disease. In addition, six metastatic lesions were detected in five patients with stage III disease at operation that were resected prior to the start of FOLFOX therapy. These 18 lesions were regarded as 'pre-FOLFOX\' metastatic lesions. The pre-FOLFOX metastases were found in the liver (11 lesions), lung (5 lesions), as a local recurrence (1 lesion) and as a subcutaneous recurrence (1 lesion). Meanwhile, 24 metastatic lesions in the 21 patients were detected during or after FOLFOX therapy. These lesions were regarded as 'post-FOLFOX\' metastatic lesions. The post-FOLFOX metastases were found in the liver, lung, as a local recurrence and lymph node in 6, 14, 3 and 1 patients, respectively.

The median number of FOLFOX therapy cycles administered was 9 (3--12 cycles). Five patients experienced relapse during FOLFOX therapy (case 1, 2, 3, 7 and 12), whereas the remaining 16 patients experienced relapse after the end of FOLFOX therapy. The median disease-free survival, calculated from the time of the last operation until post-FOLFOX recurrence, was 409 days (97--1077). The median period from the start of FOLFOX therapy until recurrence was 373 days (35--1029). Relapses developed within 180 days after the end of FOLFOX therapy in 10 of the 21 patients ([Table 2](#tbl2){ref-type="table"}).

Mutational status of *KRAS* and other genes
-------------------------------------------

The mutational statuses of *KRAS* and other genes in primary and metastatic lesions are shown in [Table 3](#tbl3){ref-type="table"}. Mutations in *KRAS* codons 12 and 13 were detected in 13 of the 21 primary colorectal tumours. Among the remaining eight tumours with wild-type *KRAS* codons 12 and 13, two tumours exhibited *KRAS* codon 146 mutations (A146V and A146T) and one tumour exhibited *NRAS* codon 61 mutation (Q61H). Two tumours exhibited mutations in *PIK3CA* codon 542 (E542K), one tumour exhibited a *KRAS* G12S mutation and one tumour had no mutations in any of the genes examined. No apparent mutations of *KRAS* codon 61, *NRAS* codon 12 or 13, *BRAF* codon 600, or *PIK3CA* codon 1047 were detected in any sample in this study.

The degree of concordance of the gene mutations in primary and pre-FOLFOX metastatic lesions was examined. In case 10, a *KRAS* G12A mutation was detected in the primary lesion, whereas the metastatic lesion in the lung had wild-type *KRAS*. Although the histological features of the lung lesion were consistent with metastatic adenocarcinoma of the colon, no mutations in the metastatic lesion were detected, even after repeated high-sensitivity examinations. The remaining 17 metastatic lesions in 14 patients, including 2 liver metastatic lesions in case 10, showed the same mutational statuses as the primary tumours for all of the genes examined.

Then, the mutational statuses of the post-FOLFOX metastatic lesions were examined. The mutational statuses of all genes examined were identical in the 21 primary tumours and the corresponding 24 post-FOLFOX metastatic lesions, regardless of the sites involved, duration of FOLFOX treatment or disease-free survival period.

Discussion
==========

Previous studies have reported a high concordance rate of the *KRAS* mutations in primary and metastatic tumours ([@bib25]; [@bib22]; [@bib30]; [@bib33]; [@bib31]; [@bib11]; [@bib27]; [@bib14]; [@bib23]; [@bib26]; [@bib5]; [@bib16]; [@bib19]). However, in patients receiving long-term chemotherapy, the effects of genotoxic chemotherapies, such as oxaliplatin, have not been well investigated.

In this study, we examined 21 patients with metastatic colorectal cancer who received adjuvant FOLFOX therapy. The recurrent tumours in three patients who showed relapse within 4 months after the primary surgery or during the first 3 or 4 cycles of adjuvant FOLFOX therapy (cases 1--3) were regarded as synchronous metastases arising from micrometastases that likely existed prior to the start of the adjuvant chemotherapy. The remaining 18 patients who developed relapses more than 8 months from the end of adjuvant FOLFOX therapy or after more than 6 cycles of adjuvant FOLFOX therapy were regarded as having metachronous metastatic tumours that had developed after exposure to oxaliplatin. Among these cases, tumour relapse occurred within 180 days after FOLFOX therapy in 7 patients and more than 180 days after FOLFOX therapy in the remaining 11 patients. Regardless of the treatment duration, 8 of the primary tumours with wild-type *KRAS* codons 12 and 13 did not acquire *KRAS* mutations. The remaining tumours with *KRAS* mutations also did not show additional mutations after FOLFOX therapy. Furthermore, none of the other genes that might potentially affect the efficacy of anti-EGFR antibody therapy were altered.

*KRAS*, *NRAS* and *BRAF* mutations are all regarded as strong driver mutations that induce cell proliferation. These mutations might be acquired in the early stages of carcinogenesis and have generally been reported as mutually exclusive ([@bib4]). Consistent with this observation, the *KRAS* and *NRAS* mutations in this study were found to be mutually exclusive. In the rest of the tumours, other unidentified driver mutations or amplifications may have activated the signalling pathways promoting cell proliferation. Considering the exclusive nature of the tested mutations, the acquisition of additional driver mutations may not be advantageous to these tumour cells for clonal selection. This could be one explanation for why the mutational statuses of *KRAS* and other genes were not altered during the development of metastatic tumours.

Our findings suggest that both the primary tumours and metastatic tumours arising during or after FOLFOX therapy could be valid sources of DNA for *KRAS* testing prior to treatment with anti-EGFR antibodies, although the number of cases in this study was limited. This finding should be further confirmed in a larger number of cases. Though collecting surgically resected metastatic tumour tissues is often difficult, circulating tumour cells may be a useful alternative DNA source for highly reliable and sensitive mutation detection systems such as the ARMS/Scorpion method for further analyses.

The study was supported by the National Cancer Center Research and Development Fund, 23-A-2, awarded to KT and TY.

###### Characteristics

  **Patient characteristics**                     **Number**
  ------------------------------------------- -------------------
  Sex (female/male)                                  8/13
  Median age (range)                           64 (36--75) years
                                                        
  *Primary tumour site*                       
   Colon                                               8
   Rectum                                             13
                                                        
  *Histopathological type of primary site*    
   Well-differentiated adenocarcinoma                  5
   Moderately differentiated adenocarcinoma           14
   Mucinous adenocarcinoma                             2
                                                        
  *Stage before initial operation*            
   III                                                12
   IV (synchronous metastases)                         9
                                                        
  **Tumour site characteristics**             
  *Metastases*                                
   Pre-FOLFOX                                         18
    Synchronous                                       12
    Metachronous                                       6
   Post-FOLFOX                                        24
                                                        
  *Sites of metastases*                       
   Pre-FOLFOX                                           
    Liver                                             11
    Lung                                               5
    Local recurrence                                   1
    Subcutaneous                                       1
  * Post-FOLFOX*                                        
    Liver                                              6
    Lung                                              14
    Local recurrence                                   3
    Lymph node                                         1

###### FOLFOX treatment, metastasis status and tumour recurrence sites

  **Case**   **Primary site**    **Histopathological type**   **Pre-FOLFOX metastatic site**   **Synchronous/ metachronous**  **FOLFOX cycles**   **DFS (days)**   **Days from end of FOFLOX until recurrence**   **Post-FOLFOX recurrence site**
  ---------- ------------------ ---------------------------- -------------------------------- ------------------------------- ------------------- ---------------- ---------------------------------------------- ---------------------------------
  1          Rectum                         Mode                           ---                              ---               3                   124              6                                              Liver
  2          Colon                          Mode                          Liver                         Synchronous           4                   97               −16[a](#t2-fn2){ref-type="fn"}                 Liver
  3          Colon                          Mode                          Liver                         Synchronous           4                   116              26                                             Liver
  4          Rectum                         Well                     Local recurrence                  Metachronous           4                   469              363                                            Local recurrence
  5          Rectum                         Mode                           ---                              ---               5                   827              603                                            Lung
  6          Colon                          Mode                           ---                              ---               5                   350              244                                            Lymph node
  7          Rectum                         Mode                          Liver                         Synchronous           8                   214              1                                              Lung
                                                                           Lung                         Synchronous                                                                                                
  8          Rectum                         Muc                            ---                              ---               8                   538              318                                            Lung
  9          Colon                          Well                           ---                              ---               8                   1077             903                                            Liver
  10         Colon                          Mode                          Liver                         Synchronous           8                   344              120                                            Lung
                                                                          Liver                         Synchronous                                                                                               Lung
                                                                           Lung                         Synchronous                                                                                                
  11         Colon                          Muc                            Lung                         Synchronous           9                   721              401                                            Lung
  12         Rectum                         Well                          Liver                         Synchronous           9                   109              −88[a](#t2-fn2){ref-type="fn"}                 Liver
  13         Rectum                         Mode                          Liver                        Metachronous           11                  328              120                                            Liver
                                                                           Lung                        Metachronous                                                                                                
  14         Rectum                         Mode                       Subcutaneous                    Metachronous           12                  519              156                                            Lung
  15         Colon                          Mode                           ---                              ---               12                  388              176                                            Local recurrence
  16         Rectum                         Mode                          Liver                         Synchronous           12                  466              210                                            Lung
  17         Rectum                         Well                           Lung                         Synchronous           12                  556              264                                            Lung
  18         Colon                          Mode                          Liver                        Metachronous           12                  531              231                                            Lung
                                                                                                                                                                                                                  Lung
  19         Rectum                         Mode                          Liver                         Synchronous           12                  409              217                                            Lung
  20         Rectum                         Mode                           ---                              ---               12                  455              243                                            Local recurrence
  21         Rectum                         Well                          Liver                        Metachronous           12                  346              71                                             Lung
                                                                                                                                                                                                                  Lung

Abbreviations: DFS=disease-free survival; mode=moderately differentiated adenocarcinoma; muc=mucinous adenocarcinoma; well=well-differentiated adenocarcinoma.

The cases that FOLFOX therapies were administered after recurrence.

###### Mutational status of *KRAS* and other genes

  **Case**   **Primary site**      **Mutation status**     **Pre-FOLFOX metastatic site**     **Mutation status**     **Post-FOLFOX recurrence site**     **Mutation status**
  ---------- ------------------ ------------------------- -------------------------------- ------------------------- --------------------------------- -------------------------
  1          Rectum                     KRAS G12D                       ---                           ---                          Liver                       KRAS G12D
  2          Colon                      KRAS G12D                      Liver                       KRAS G12D                       Liver                       KRAS G12D
  3          Colon                      KRAS G12D                      Liver                       KRAS G12D                       Liver                       KRAS G12D
  4          Rectum                     KRAS G12R                 Local recurrence                 KRAS G12R                 Local recurrence                  KRAS G12R
  5          Rectum                     KRAS G12D                       ---                           ---                          Lung                        KRAS G12D
  6          Colon                         WT                           ---                           ---                           LN                            WT
  7          Rectum                     KRAS G12S                      Liver                       KRAS G12S                       Lung                        KRAS G12S
                                                                        Lung                       KRAS G12S                                                        
  8          Rectum                        WT                           ---                           ---                          Lung                           WT
  9          Colon                         WT                           ---                           ---                          Liver                          WT
  10         Colon                      KRAS G12A                      Liver                       KRAS G12A                       Lung                        KRAS G12A
                                                                       Liver                       KRAS G12A                       Lung                        KRAS G12A
                                                                        Lung                          WT                                                            
  11         Colon                      KRAS G13D                       Lung                       KRAS G13D                       Lung                        KRAS G13D
  12         Rectum                    KRAS A146V                      Liver                      KRAS A146V                       Liver                      KRAS A146V
  13         Rectum                     KRAS G12V                      Liver                       KRAS G12V                       Liver                       KRAS G12V
                                                                        Lung                       KRAS G12V                                                        
  14         Rectum                     KRAS G12D                   Subcutaneous                   KRAS G12D                       Lung                        KRAS G12D
  15         Colon                         WT                           ---                           ---                    Local recurrence                     WT
  16         Rectum              KRAS G12S, PIK3CA E542K               Liver                KRAS G12S, PIK3CA E542K                Lung                 KRAS G12S, PIK3CA E542K
  17         Rectum                     KRAS G12D                       Lung                       KRAS G12D                       Lung                        KRAS G12D
  18         Colon                      KRAS G12D                      Liver                       KRAS G12D                       Lung                        KRAS G12D
                                                                                                                                   Lung                        KRAS G12D
  19         Rectum                     NRAS Q61H                      Liver                       NRAS Q61H                       Lung                        NRAS Q61H
  20         Rectum                   PIK3CA E542K                      ---                           ---                    Local recurrence                PIK3CA E542K
  21         Rectum                    KRAS A146V                      Liver                      KRAS A146V                       Lung                       KRAS A146V
                                                                                                                                   Lung                       KRAS A146V

Abbreviations: LN= lymph node; WT= wild-type.
